We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Incivek Approval Escalates Race for Hepatitis C Market
Incivek Approval Escalates Race for Hepatitis C Market
May 27, 2011
Vertex’s oral hepatitis C therapy Incivek, which received FDA approval May 23, will begin sales this week at a much higher price than its direct competitor, Merck’s oral Victrelis, approved May 13.